Navigation Links
Innovative method for creating a human cytomegalovirus vaccine outlined

Each year, about 40,000 children are born infected with human cytomegalovirus, or CMV, and about 8,000 of these children suffer permanent disabilities due to the virus ?almost one an hour. These disabilities can include hearing loss, vision loss, mental disability, a lack of coordination, and seizures. According to the Centers for Disease Control and Prevention, CMV is as common a cause of serious disability as Down syndrome, fetal alcohol syndrome, or neural tube defects.

Because of the dangers posed by the virus to infants, the Institute of Medicine has declared that development of a CMV vaccine should be one of the highest priorities for vaccine makers. Now, in a new study in the August 1 issue of The Journal of Virology, researchers at The Wistar Institute outline an innovative approach that could be used to create such a vaccine.

The Wistar scientists began with the observation that mice harbor a species-specific form of CMV that is unable to sustain an infection in humans and is completely harmless to them. They then asked whether, using recombinant technologies, there might not be a way to shift the mouse-specific virus closer to the human-specific virus to generate a version of the virus able to elicit a protective immune response but not a dangerous infection in humans.

With this goal, the researchers began to systematically introduce selected genes from human CMV into the genome of mouse CMV in the laboratory. The result was a novel form of CMV virus that infected human cells well enough that it might trigger an immune response but not well enough to sustain an infection.

"It should be possible to develop a safe and effective CMV vaccine using the method we've described in our study," says Gerd G. Maul, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and senior author on the new study. "Success will depend on achieving a certain balance between the immune-stimulating genes from the human virus
'"/>

Source:The Wistar Institute


Page: 1 2

Related biology news :

1. Innovative collaboration brings Arctic science into the classroom
2. Innovative coating could give medical implants a longer life
3. Innovative movies show real-time immune-cell activity within tumors
4. Color-blind method opens new doors in DNA sequencing
5. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
6. Studies reveal methods viruses use to sidestep immune system
7. An entropy-based gene selection method for cancer classification using microarray data
8. New methods of gene delivery using lasers
9. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
10. Shift of weather patterns necessitates rethinking of reforestation methods
11. Scientists use manufacturing methods to reconstruct mastodon
Post Your Comments:
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... the University of Leeds, UK, the Charit University Medical ... Medicine (MDC) in Berlin, Germany, have discovered a new ... identified how ,junk, DNA promotes the growth of cancer ... (University of Leeds) and Dr Stephan Mathas (Charit, MDC) ...
... estimated that nearly 1.5 million Americans have been diagnosed with ... are believed to have some form of autism, according to ... and Prevention (CDC). Find out what new research and treatment ... ASD seen over the past few decades at a panel ...
... Heart and liver transplant recipients are at particularly ... donated organ, researchers report at the 2nd European Lung ... such cancers in these patients to maximize the chance ... for decades that the immunosuppressive drugs given to transplant ...
Cached Biology News:'Junk DNA' drives cancer growth 2Expert panel to discuss autism spectrum disorders 2Lung cancer risk particularly high for heart and liver transplant recipients 2
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Physicists at the University of California, Berkeley, have built the ... the diameter of a human hair that requires only a ... , The scientists successfully received their first FM broadcast last ... Boys, "Good Vibrations" transmitted from across the room. In homage ...
... 31 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; ... its biotech method,for 7ACA production has been ... believes this achievement validates the Company,s research,and ... This,technology would bring immediate benefits to production ...
... CRANBURY, N.J., Oct. 31 Amicus Therapeutics,(Nasdaq: ... small molecule,orally-active pharmacological chaperones for the treatment ... for the third quarter of 2007.,On a ... Generally Accepted,Accounting Principles (GAAP), Amicus announced a ...
Cached Biology Technology:World's smallest radio uses single nanotube to pick up good vibrations 2World's smallest radio uses single nanotube to pick up good vibrations 3World's smallest radio uses single nanotube to pick up good vibrations 4Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: